 Antibodies, Monoclonal, Murine-Derived
"Antibodies, Monoclonal, Murine-Derived" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies obtained from a single clone of cells grown in mice or rats.
| Descriptor ID |
D058846
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.075 D12.776.124.790.651.114.224.075 D12.776.377.715.548.114.224.284
|
| Concept/Terms |
Antibodies, Monoclonal, Murine-Derived- Antibodies, Monoclonal, Murine-Derived
- Murine-Derived Monoclonal Antibodies
- Antibodies, Murine-Derived Monoclonal
- Monoclonal Antibodies, Murine-Derived
- Murine Derived Monoclonal Antibodies
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Murine-Derived".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Murine-Derived".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Murine-Derived" by people in this website by year, and whether "Antibodies, Monoclonal, Murine-Derived" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 2 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 3 | 3 | | 2009 | 0 | 1 | 1 | | 2010 | 2 | 1 | 3 | | 2011 | 1 | 2 | 3 | | 2012 | 0 | 1 | 1 | | 2013 | 4 | 2 | 6 | | 2014 | 4 | 1 | 5 | | 2015 | 1 | 1 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Murine-Derived" by people in Profiles.
-
Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017 Nov 01; 35(31):3538-3546.
-
Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. J Clin Oncol. 2017 Jul 10; 35(20):2260-2267.
-
Karmali R, Gordon LI. Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy. Curr Treat Options Oncol. 2017 02; 18(2):11.
-
Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao W, Vanslambrouck C, Nabhan C. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Br J Haematol. 2016 Nov; 175(4):631-640.
-
Amber KT, Kodiyan J, Bloom R, Hertl M. The controversy of hepatitis C and rituximab: A multidisciplinary dilemma with implications for patients with pemphigus. Indian J Dermatol Venereol Leprol. 2016 Mar-Apr; 82(2):182-3.
-
Bloom R, Amber KT. Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States. J Am Acad Dermatol. 2015 Aug; 73(2):337-8.
-
Mittal N, Zhu B, Gaitonde S, Lu Y, Schmidt ML. A unique description of stage IV extranodal marginal zone lymphoma (EMZL) in an adolescent associated with gamma heavy chain disease. Pediatr Blood Cancer. 2015 May; 62(5):905-8.
-
Makatsori M, Kiani-Alikhan S, Manson AL, Verma N, Leandro M, Gurugama NP, Longhurst HJ, Grigoriadou S, Buckland M, Kanfer E, Hanson S, Ibrahim MA, Grimbacher B, Chee R, Seneviratne SL. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014 Oct; 107(10):821-8.
-
Dang L, Dang X, Koralnik IJ, Todd PK. JC polyomavirus granule cell neuronopathy in a patient treated with rituximab. JAMA Neurol. 2014 Apr; 71(4):487-9.
-
Hadley I, Jain R, Sreih A. Nonvasculitic autoimmune meningoencephalitis after rituximab: the potential downside of depleting regulatory B cells in the brain. J Clin Rheumatol. 2014 Apr; 20(3):163-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|